Compare MEDINOVA DIA with DR.AGAR.EYE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

MEDINOVA DIAG. vs DR.AGAR.EYE - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    MEDINOVA DIAG. DR.AGAR.EYE MEDINOVA DIAG./
DR.AGAR.EYE
 
P/E (TTM) x 13.0 22.8 57.1% View Chart
P/BV x - 6.4 - View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 MEDINOVA DIAG.   DR.AGAR.EYE
EQUITY SHARE DATA
    MEDINOVA DIAG.
Mar-21
DR.AGAR.EYE
Mar-21
MEDINOVA DIAG./
DR.AGAR.EYE
5-Yr Chart
Click to enlarge
High Rs31416 7.4%   
Low Rs11188 6.1%   
Sales per share (Unadj.) Rs12.8297.5 4.3%  
Earnings per share (Unadj.) Rs1.9-3.1 -62.3%  
Cash flow per share (Unadj.) Rs2.637.6 7.0%  
Dividends per share (Unadj.) Rs00-  
Avg Dividend yield %00-  
Book value per share (Unadj.) Rs-7.2116.3 -6.2%  
Shares outstanding (eoy) m9.984.70 212.3%   
Bonus / Rights / Conversions ---  
Price / Sales ratio x1.71.0 163.1%   
Avg P/E ratio x11.1-98.7 -11.2%  
P/CF ratio (eoy) x8.18.0 100.2%  
Price / Book Value ratio x-2.92.6 -112.9%  
Dividend payout %00-   
Avg Mkt Cap Rs m2111,420 14.9%   
No. of employees `000NANA-   
Total wages/salary Rs m17322 5.4%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m1271,398 9.1%  
Other income Rs m119 7.0%   
Total revenues Rs m1291,418 9.1%   
Gross profit Rs m30298 10.1%  
Depreciation Rs m7191 3.8%   
Interest Rs m570 6.7%   
Profit before tax Rs m2057 34.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m172 0.8%   
Profit after tax Rs m19-14 -132.4%  
Gross profit margin %23.621.3 110.5%  
Effective tax rate %2.9125.1 2.3%   
Net profit margin %14.9-1.0 -1,452.5%  
BALANCE SHEET DATA
Current assets Rs m16441 3.5%   
Current liabilities Rs m80479 16.6%   
Net working cap to sales %-50.2-2.7 1,832.2%  
Current ratio x0.20.9 21.2%  
Inventory Days Days1972 25.9%  
Debtors Days Days188229 82.1%  
Net fixed assets Rs m251,234 2.0%   
Share capital Rs m10047 211.9%   
"Free" reserves Rs m-172500 -34.3%   
Net worth Rs m-72547 -13.2%   
Long term debt Rs m33100 32.9%   
Total assets Rs m411,674 2.4%  
Interest coverage x5.21.8 287.2%   
Debt to equity ratio x-0.50.2 -249.6%  
Sales to assets ratio x3.10.8 374.2%   
Return on assets %58.03.3 1,760.0%  
Return on equity %-26.5-2.6 1,005.5%  
Return on capital %-61.819.6 -314.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m00-   
Fx outflow Rs m07 0.0%   
Net fx Rs m0-7 0.0%   
CASH FLOW
From Operations Rs m19339 5.7%  
From Investments Rs m-3-110 2.8%  
From Financial Activity Rs m-14-76 18.1%  
Net Cashflow Rs m2153 1.6%  

Share Holding

Indian Promoters % 62.1 72.4 85.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 0.0 -  
FIIs % 0.0 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 37.9 27.6 137.1%  
Shareholders   9,906 2,741 361.4%  
Pledged promoter(s) holding % 0.0 99.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare MEDINOVA DIAG. With:   FORTIS HEALTHCARE    INDRAPRASTHA MEDICAL    THYROCARE TECHNOLOGIES    DR. LAL PATHLABS    KIMS    



Today's Market

Indian Indices End Flat Amid High Volatility; Maruti Suzuki & Tech Mahindra Among Top Losers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended marginally lower.

Related Views on News

ITC to Coal India: Are these the Best Dividend Stocks You can Count on? (Views On News)

Jan 25, 2022

A list of companies that have paid dividends regularly for years, creating value for shareholders.

JLR, Corus, Tetley - Was Ratan Tata's Go Global Strategy Right Afterall? (Views On News)

Jan 20, 2022

Ratan Tata took the lead in global acquisitions and changed the mindset of India's business leaders. Was he successful after all?

Top 4 Oxygen Stocks to Add to Your Watchlist (Views On News)

Jan 12, 2022

Amid a surge in Covid cases, states have been asked to keep adequate stock of medical oxygen for at least 48 hours.

Omicron: Sectors to Buy and Avoid in 2022 (Views On News)

Jan 11, 2022

We take a look at how stocks of 6 major sectors were impacted, the last time lockdowns were imposed and what we can learn from it.

Watch Out for these 4 Indian Companies Betting Big on EV Supply Chain (Views On News)

Jan 11, 2022

The upside in supply chain players could be huge but a delay in the transition to EVs, or any policy related hiccups could end the momentum.

More Views on News

Most Popular

These 5 Penny Stocks are Held by Rakesh Jhunjhunwala. Worth a Look?(Views On News)

Jan 18, 2022

Rakesh Jhunjhunwala is holding these penny stocks in his portfolio for several years now.

Tech Mahindra's CTC Acquisition: Too Expensive?(Views On News)

Jan 18, 2022

Tech Mahindra's acquisition of European IT-company fails to excite investors.

5 Hidden Tata Group Companies to Add to Your Watchlist(Views On News)

Jan 18, 2022

Here's all you need to know about these five Tata group stocks that aren't as popular as the others.

Insiders are Buying into these 6 Stocks Aggressively. More Details here...(Views On News)

Jan 19, 2022

While promoter holding is an important parameter, it should not be the sole reason for buying a stock.

Top Indian Drone Companies to Watch Out for in 2022(Views On News)

Jan 21, 2022

Several companies are adopting drone technology for regular business operations.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

MEDINOVA DIAG. SHARE PRICE


Jan 28, 2022 (Close)

TRACK MEDINOVA DIAG.

  • Track your investment in MEDINOVA DIAG. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON MEDINOVA DIAG.

MEDINOVA DIAG. 8-QTR ANALYSIS

COMPARE MEDINOVA DIAG. WITH

MARKET STATS